Magdi S Yacoub, Tamer El-Nakhal, Elfatih A Hasabo, Nahla Shehata, Karim Wilson, Kenzy H Ismail, Mohamed S Bakr, Maram Mohsen, Asmaa Mohamed, Eslam Abdelazim, Hossam T Ali, Ziad Soliman, Ahmed Sayed, Kerollos Abdelsayed, Kadir Caliskan, Osama Soliman
Hypertrophic cardiomyopathy (HCM) is the most common heritable myocardial disorder worldwide. Current pharmacological treatment options are limited. Mavacamten, a first-in-class cardiac myosin inhibitor, targets the main underlying pathology of HCM. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of Mavacamten in patients with HCM. PRISMA flow chart was utilized using PubMed, SCOPUS, and Cochrane databases for all up-to-date studies using pre-defined keywords. Pre-specified efficacy outcomes comprised several parameters, including an improvement in peak oxygen consumption (pVO2) and ≥ 1 NYHA class, the need for septal reduction therapy (SRT), change from baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ), changes in biochemical markers and LVEF, along with peak left ventricular outflow tract gradient at rest and after Valsalva maneuver...
March 2024: Heart Failure Reviews